Overview
- Novo Nordisk said Monday it stopped a pivotal study after semaglutide failed to slow cognitive decline in people with mild, early-stage Alzheimer’s.
- Study clinicians were instructed to inform participants of the outcome and discontinue the study medication.
- The tablet form tested was Rybelsus, which contains semaglutide and is approved for type-2 diabetes, not Alzheimer’s.
- Novo Nordisk reported improvements in certain Alzheimer’s biomarkers that did not translate into clinical benefit.
- Company shares fell by up to about 10 percent, and initial trial data are slated for presentation at the CTAD meeting on December 3, as investigators consider whether earlier intervention merits further study.